[go: up one dir, main page]

MX2009002504A - Polipeptidos acuareticos y natriureticos que carecen de actividad vasodilatadora. - Google Patents

Polipeptidos acuareticos y natriureticos que carecen de actividad vasodilatadora.

Info

Publication number
MX2009002504A
MX2009002504A MX2009002504A MX2009002504A MX2009002504A MX 2009002504 A MX2009002504 A MX 2009002504A MX 2009002504 A MX2009002504 A MX 2009002504A MX 2009002504 A MX2009002504 A MX 2009002504A MX 2009002504 A MX2009002504 A MX 2009002504A
Authority
MX
Mexico
Prior art keywords
aquaretic
natriuretic
polypeptides lacking
vasodilatory activity
natriuretic polypeptides
Prior art date
Application number
MX2009002504A
Other languages
English (en)
Inventor
Horng H Chen
John C Burnett Jr
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of MX2009002504A publication Critical patent/MX2009002504A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Este documento proporciona polipéptidos acuaréticos y natriuréticos. Por ejemplo, este documento proporciona polipéptidos que tienen actividades acuaréticas y/o natriuréticas. En algunos casos, un polipéptido proporcionado en la presente puede tener actividades acuaréticas y natriuréticas, mientras que carece de la capacidad para disminuir la presión sanguínea. Este documento también proporciona métodos y materiales para inducir las actividades acuaréticas y/o natriuréticas en un mamífero.
MX2009002504A 2006-09-08 2007-09-07 Polipeptidos acuareticos y natriureticos que carecen de actividad vasodilatadora. MX2009002504A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82502806P 2006-09-08 2006-09-08
PCT/US2007/077900 WO2008031045A2 (en) 2006-09-08 2007-09-07 Aquaretic and natriuretic polypeptides lacking vasodilatory activity

Publications (1)

Publication Number Publication Date
MX2009002504A true MX2009002504A (es) 2009-05-22

Family

ID=39158102

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009002504A MX2009002504A (es) 2006-09-08 2007-09-07 Polipeptidos acuareticos y natriureticos que carecen de actividad vasodilatadora.

Country Status (9)

Country Link
US (4) US8283318B2 (es)
EP (2) EP2295445A1 (es)
JP (1) JP2010502231A (es)
CN (1) CN101600731A (es)
BR (1) BRPI0716228A2 (es)
CA (1) CA2662453A1 (es)
IL (1) IL197432A0 (es)
MX (1) MX2009002504A (es)
WO (1) WO2008031045A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1759001T3 (da) 2004-04-21 2011-08-01 Enobia Pharma Inc Konjugat til tilførsel til knogler og fremgangsmåde til fremstilling deraf ved at målrette proteiner til knoglen
US8283318B2 (en) 2006-09-08 2012-10-09 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity
US20110152194A1 (en) * 2008-06-06 2011-06-23 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
WO2010078325A2 (en) 2008-12-29 2010-07-08 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
US20120108514A1 (en) 2009-07-09 2012-05-03 University Of Iowa Research Foundation Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
ES2556336T3 (es) * 2009-08-27 2016-01-15 Kyoko Endo Agente terapéutico para la rinitis
KR20190000368A (ko) * 2010-03-31 2019-01-02 더 호스피탈 포 식 칠드런 심근 경색 후 결과를 개선시키기 위한 원격 허혈 처치의 사용
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
WO2012115772A2 (en) 2011-02-25 2012-08-30 Medtronic, Inc. Therapy for kidney disease and/or heart failure
US9102707B2 (en) 2011-08-30 2015-08-11 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2013033675A1 (en) 2011-09-02 2013-03-07 Medtronic, Inc. Chimeric natriuretic peptide compositions and methods of preparation
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US10414808B2 (en) 2012-05-18 2019-09-17 Janssen Biotech, Inc. Huwentoxin-IV variants and methods of use
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
EP2874540B8 (en) * 2012-07-19 2018-12-19 Fresenius Medical Care Deutschland GmbH Calibration of a body parameter for monitoring dialysis
CA2926052A1 (en) 2013-10-03 2015-04-09 Janssen Biotech, Inc. Protoxin-ii variants and methods of use
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
CA2967851C (en) 2014-12-05 2024-02-27 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
MA41642A (fr) 2015-03-03 2018-01-09 Janssen Biotech Inc Variants de protoxine ii et méthodes d'utilisation
JP6985151B2 (ja) 2015-04-02 2021-12-22 ヤンセン バイオテツク，インコーポレーテツド プロトキシン−ｉｉ変異体及びその使用方法
AU2016308624B2 (en) 2015-08-17 2022-06-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
JP2018533571A (ja) 2015-10-30 2018-11-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド 患者の頭蓋縫合早期癒合症を治療するための方法
CN115177720A (zh) 2016-01-08 2022-10-14 阿森迪斯药物生长障碍股份有限公司 具有低npr-c结合的控制释放cnp激动剂
WO2017118693A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
CA3008015A1 (en) * 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release c-type natriuretic peptide agonists with increased neutral endopeptidase stability
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436020A4 (en) 2016-04-01 2019-12-25 Alexion Pharmaceuticals, Inc. METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
EP4223309A1 (en) 2016-09-29 2023-08-09 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
KR20240158374A (ko) 2017-03-31 2024-11-04 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
JP2021519590A (ja) 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CN113423384B (zh) 2019-02-11 2024-01-05 阿森迪斯药物生长障碍股份有限公司 Cnp缀合物的干燥药物制剂
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12077561B2 (en) 2022-11-02 2024-09-03 Novo Nordisk A/S CNP compounds
WO2025054172A1 (en) 2023-09-05 2025-03-13 E-Star Biotech, LLC Formulations of manp and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034074A (en) * 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4935492A (en) 1987-12-24 1990-06-19 California Biotechnology Inc. Cyclic analogs of atrial natriuretic peptides
JP2848411B2 (ja) * 1988-08-18 1999-01-20 サイオス インコーポレイテッド 心房性ナトリウム利尿ペプチドクリアランス阻害剤
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5296347A (en) * 1991-02-08 1994-03-22 Ciba Corning Diagnostics Corp. Bridge immunoassay
AU6360394A (en) * 1993-03-03 1994-09-26 Mayo Foundation For Medical Education And Research Vasonatrin peptide and analogs thereof
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
EP2308889B1 (en) * 2003-06-20 2018-05-23 Mayo Foundation For Medical Education And Research Isoforms of brain natriuretic peptide
AU2005207886A1 (en) * 2004-01-27 2005-08-11 Compugen Usa, Inc. Novel brain natriuretic peptide variants and methods of use thereof
US7731965B2 (en) * 2005-02-17 2010-06-08 Abbott Lab Human ring specific BNP antibodies
US8283318B2 (en) 2006-09-08 2012-10-09 Mayo Foundation For Medical Education And Research Aquaretic and natriuretic polypeptides lacking vasodilatory activity

Also Published As

Publication number Publication date
EP2295445A1 (en) 2011-03-16
US9469682B2 (en) 2016-10-18
EP2059524A2 (en) 2009-05-20
WO2008031045A3 (en) 2008-04-24
EP2059524A4 (en) 2009-11-25
US20130023478A1 (en) 2013-01-24
CN101600731A (zh) 2009-12-09
WO2008031045A2 (en) 2008-03-13
BRPI0716228A2 (pt) 2013-10-15
JP2010502231A (ja) 2010-01-28
IL197432A0 (en) 2011-08-01
US20150376255A1 (en) 2015-12-31
US8283318B2 (en) 2012-10-09
US20130296241A1 (en) 2013-11-07
US9102757B2 (en) 2015-08-11
US8530422B2 (en) 2013-09-10
CA2662453A1 (en) 2008-03-13
US20100197574A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
MX2009002504A (es) Polipeptidos acuareticos y natriureticos que carecen de actividad vasodilatadora.
WO2009086126A3 (en) Natriuretic polypeptides
WO2010048308A3 (en) Natriuretic polypeptides
EP2765139A3 (en) Natriuretic polypeptides
WO2010002583A3 (en) Natriuretic polypeptides with unique pharmacologic profiles
WO2007035600A3 (en) Natriuretic activities
IL196931A (en) Variable polypeptides indicating the presence of sodium lacking blood pressure lowering properties and their uses
CA120115S (en) Container
CA118619S (en) Hinged container
MX338336B (es) Polipeptidos de insulina modificados y sus usos.
CA119544S (en) Commuter mug
CA112307S (en) Razor cartridge
CA118308S (en) Container with cover
CA114056S (en) Teapot
AU304945S (en) Inverted container
CA118083S (en) Bottle
CA122160S (en) Bottle
CA115998S (en) Holder for a scrubber
CA112740S (en) Razor
CA121128S (en) Container
CA115463S (en) Bucket
CA114740S (en) Hair trimmer
IL173104A0 (en) Siva and ubiquintination
IL192400A (en) A polypeptide with recombinant esterase and esterase activity and its use
CA119969S (en) Helicopter fuel tank lock component

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal